Silverback Therapeutics, Inc.
Silverback Therapeutics, Inc. is listed today as ARS Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2020 | $85 M | No. 4 | $50 to $250 million | equity | SEC | |
| Mar 2020 | $32 M | No. 3 | $10 to $50 million | equity | SEC | |
| Sep 2018 | $13 M | No. 2 | $10 to $50 million | equity | SEC | |
| Apr 2016 | $10 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company ARS Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Revenue under collaboration agreements $9.72 million (12%), Revenue under supply agreements $2.37 million (3%).
Annual report (SEC XBRL) · Dec 2025
Silverback Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2020).
SEC Form D · Oct 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2020
Products and services#
No products or services of Silverback Therapeutics, Inc. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| OrbiMed Capital GP VI LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Presidio Management Group XII, L.L.C. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| U.S. Venture Partners XII-A, L.P. | Venture capital | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| U.S. Venture Partners XII, L.P. | Venture capital | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 31 investors.
Largest shareholders today
Institutions holding ARS Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- Ra Capital Management, L.P.$47 M10.80%
- Rubric Capital Management LP$37 M8.50%
- Orbimed Advisors LLC$36 M8.24%
- Deerfield Management Company, L.P.$32 M7.46%
- BlackRock, Inc.$24 M5.55%
- SR One Capital Management, LP$17 M3.99%
- State Street Corp$16 M3.67%
- UBS Group AG$16 M3.65%
- Millennium Management LLC$14 M3.25%
- Tyro Capital Management LLC$14 M3.18%
- Vanguard Capital Management LLC$11 M2.49%
- Capital World Investors$8 M1.95%
- Aberdeen Group plc$7 M1.69%
- Geode Capital Management, LLC$7 M1.59%
- Janney Montgomery Scott LLC$7 M1.53%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Laura Shawver | Executive officer | Oct 2020 |
| Peter Thompson | Executive officer | Mar 2020 |
| Peter A. Thompson | Executive officer | Sep 2018 |
| Jonathan L. Root | Director | Oct 2020 |
| Laura Shawver | Director | Oct 2020 |
| Peter A. Thompson | Director | Oct 2020 |
| Robert L. Hershberg | Director | Oct 2020 |
| Saqib L. Islam | Director | Oct 2020 |
| Scott L. Platshon | Director | Oct 2020 |
| Thilo L. Schroeder | Director | Oct 2020 |
| Vickie L. Capps | Director | Oct 2020 |
| Jonathan Root | Director | Mar 2020 |
| Peter Thompson | Director | Mar 2020 |
| Robert Hershberg | Director | Mar 2020 |
| Saqib Islam | Director | Mar 2020 |
| Thilo Schroeder | Director | Mar 2020 |
| Robert A. Hershberg | Director | Sep 2018 |
| Saqib A. Islam | Director | Sep 2018 |
About
Biotech company.
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.